Impact of Misdiagnosis in Case-Control Studies of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

João Malato, Luís Graça, Nuno Sepúlveda
Author Information
  1. João Malato: Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal. ORCID
  2. Luís Graça: Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal. ORCID
  3. Nuno Sepúlveda: CEAUL-Centro de Estatística e Aplicações da Universidade de Lisboa, 1749-016 Lisboa, Portugal. ORCID

Abstract

Misdiagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) can occur when different case definitions are used by clinicians (relative misdiagnosis) or when failing the genuine diagnosis of another disease (misdiagnosis in a strict sense). This problem translates to a recurrent difficulty in reproducing research findings. To tackle this problem, we simulated data from case-control studies under misdiagnosis in a strict sense. We then estimated the power to detect a genuine association between a potential causal factor and ME/CFS. A minimum power of 80% was obtained for studies with more than 500 individuals per study group. When the simulation study was extended to the situation where the potential causal factor could not be determined perfectly (e.g., seropositive/seronegative in serological association studies), the minimum power of 80% could only be achieved in studies with more than 1000 individuals per group. In conclusion, current ME/CFS studies have suboptimal power under the assumption of misdiagnosis. This power can be improved by increasing the overall sample size using multi-centric studies, reporting the excluded illnesses and their exclusion criteria, or focusing on a homogeneous cohort of ME/CFS patients with a specific pathological mechanism where the chance of misdiagnosis is reduced.

Keywords

References

  1. J Clin Pathol. 2010 Feb;63(2):156-64 [PMID: 19955554]
  2. BMJ Open. 2019 Mar 7;9(3):e023955 [PMID: 30850404]
  3. Brain Behav Immun. 2022 May;102:362-369 [PMID: 35318112]
  4. Brain Behav Immun. 2012 Mar;26(3):401-6 [PMID: 22306456]
  5. Nat Genet. 2019 Jan;51(1):51-62 [PMID: 30578418]
  6. Fatigue. 2014 Jan 1;2(1):40-56 [PMID: 24511456]
  7. J Infect Dis. 2008 Apr 15;197(8):1171-84 [PMID: 18462164]
  8. Sci Rep. 2020 Mar 24;10(1):5267 [PMID: 32210306]
  9. Evid Rep Technol Assess (Full Rep). 2014 Dec;(219):1-433 [PMID: 30313001]
  10. Disabil Rehabil. 2023 Mar;45(5):840-847 [PMID: 35236205]
  11. Brain Behav Immun. 2021 Nov;98:101-109 [PMID: 34403736]
  12. PLoS One. 2017 Jun 12;12(6):e0179124 [PMID: 28604802]
  13. BMJ Open. 2014 Feb 07;4(2):e003973 [PMID: 24508851]
  14. Diagnostics (Basel). 2019 Aug 07;9(3): [PMID: 31394725]
  15. Front Immunol. 2019 Apr 16;10:796 [PMID: 31057538]
  16. Nat Genet. 2013 Nov;45(11):1353-60 [PMID: 24076602]
  17. J Immunol Res. 2015;2015:738030 [PMID: 26770994]
  18. Front Immunol. 2020 Jul 23;11:1400 [PMID: 32793195]
  19. Science. 2022 Jan 21;375(6578):296-301 [PMID: 35025605]
  20. Front Pediatr. 2020 Jun 12;8:293 [PMID: 32596192]
  21. Ann Intern Med. 1994 Dec 15;121(12):953-9 [PMID: 7978722]
  22. Nat Commun. 2019 Sep 6;10(1):4064 [PMID: 31492854]
  23. Front Med (Lausanne). 2021 Jul 05;8:686736 [PMID: 34291062]
  24. J Psychosom Res. 2010 Jul;69(1):17-22 [PMID: 20630259]
  25. Front Immunol. 2020 Apr 09;11:578 [PMID: 32328064]
  26. BMC Med. 2005 Dec 15;3:19 [PMID: 16356178]
  27. Fatigue. 2014 Apr 1;3(2):63-74 [PMID: 26977374]
  28. J Clin Pathol. 2005 Aug;58(8):826-32 [PMID: 16049284]
  29. Front Immunol. 2021 Apr 06;12:644548 [PMID: 33889154]
  30. Medicina (Kaunas). 2021 May 19;57(5): [PMID: 34069603]
  31. Autoimmun Rev. 2020 Jun;19(6):102527 [PMID: 32247028]
  32. J Transl Med. 2018 Oct 1;16(1):268 [PMID: 30285773]
  33. Hum Mol Genet. 2020 Sep 30;29(R1):R117-R124 [PMID: 32744306]
  34. J Transl Med. 2020 Jul 29;18(1):289 [PMID: 32727489]
  35. Antioxid Redox Signal. 2013 Nov 20;19(15):1855-60 [PMID: 23600892]
  36. BMC Med Genet. 2016 Nov 11;17(1):79 [PMID: 27835969]
  37. Front Neurol. 2018 Dec 04;9:1026 [PMID: 30564186]
  38. J Transl Med. 2017 Jul 26;15(1):162 [PMID: 28747192]
  39. Front Immunol. 2019 Nov 21;10:2684 [PMID: 31824487]
  40. Front Immunol. 2022 Jan 03;12:628741 [PMID: 35046929]
  41. J Health Psychol. 2019 Oct;24(12):1765-1769 [PMID: 28810428]
  42. Epigenetics. 2018;13(12):1174-1190 [PMID: 30516085]
  43. Front Med (Lausanne). 2022 Jun 24;9:921101 [PMID: 35814774]
  44. Front Immunol. 2021 Nov 15;12:656797 [PMID: 34867935]
  45. Medicina (Kaunas). 2020 Dec 24;57(1): [PMID: 33374291]
  46. Chronic Dis Transl Med. 2021 Mar;7(1):14-26 [PMID: 33251031]

Grants

  1. SFRH/BD/149758/2019/Fundação para a Ciência e a Tecnologia
  2. UIDB/00006/2020/Fundação para a Ciência e a Tecnologia
  3. PPN/ULM/2020/1/00069/U/00001/Narodowa Agencja Wymiany Akademickiej

Word Cloud

Created with Highcharts 10.0.0studiesmisdiagnosispowerME/CFSassociationMisdiagnosiscangenuinestrictsenseproblempotentialcausalfactorminimum80%individualsperstudygroupsimulationmyalgicencephalomyelitis/chronicfatiguesyndromeoccurdifferentcasedefinitionsusedcliniciansrelativefailingdiagnosisanotherdiseasetranslatesrecurrentdifficultyreproducingresearchfindingstacklesimulateddatacase-controlestimateddetectobtained500extendedsituationdeterminedperfectlyegseropositive/seronegativeserologicalachieved1000conclusioncurrentsuboptimalassumptionimprovedincreasingoverallsamplesizeusingmulti-centricreportingexcludedillnessesexclusioncriteriafocusinghomogeneouscohortpatientsspecificpathologicalmechanismchancereducedImpactCase-ControlStudiesMyalgicEncephalomyelitis/ChronicFatigueSyndromemisclassificationstatistical

Similar Articles

Cited By